|
市場調査レポート
商品コード
1481401
経動脈的化学塞栓療法の世界市場規模、シェア、成長分析、製品別、エンドユーザー別、技術別- 産業予測、2024年～2031年Global Transarterial Chemoembolization Market Size, Share, Growth Analysis, By Product, By End-User, By Technology - Industry Forecast 2024-2031 |
||||||
|
|
|||||||
| 経動脈的化学塞栓療法の世界市場規模、シェア、成長分析、製品別、エンドユーザー別、技術別- 産業予測、2024年～2031年 |
|
出版日: 2024年05月18日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
経動脈的化学塞栓療法の世界市場規模は2022年に168億8,000万米ドルと評価され、2023年の178億1,000万米ドルから2031年には273億3,000万米ドルに成長し、予測期間（2024年～2031年）のCAGRは5.5%で成長する見通しです。
経動脈化学塞栓療法（TACE）の世界市場は、多くの要因によって大きな成長と進化を遂げています。TACEは、主に肝臓がんの治療に用いられる低侵襲手術であり、世界の肝臓がん罹患率の上昇により需要が急増しています。アルコール消費量の増加、B型およびC型肝炎の流行、ライフスタイルの変化などの要因が、肝がんの負担増に寄与しています。さらに、医療技術や手技の進歩によりTACE手技の有効性と安全性が向上し、市場の拡大に拍車をかけています。さらに、TACEとラジオ波焼灼療法や免疫療法などの他の治療法を併用する併用療法の採用が増加していることも、その適用範囲を広げ、市場の成長を後押ししています。さらに、いくつかの国ではTACE治療に対する償還政策が優遇されており、治療成績を向上させるための研究開発が進行中であることも相まって、市場の勢いが持続すると予想されます。しかし、特定の地域では高度なヘルスケア施設へのアクセスが限られていることや、TACE手技に関連する費用が高額であることなどの課題が、市場の成長をある程度阻害する可能性があります。全体として、絶え間ない技術革新と個別化医療への注目の高まりにより、世界のTACE市場は当面さらなる発展を遂げるものと思われます。
目次
エグゼクティブサマリー
- 市場概要
- 運命の輪
調査手法
- 情報調達
- 二次データソースと一次データソース
- 市場規模予測
- 市場の危機と限界
親市場の分析
- 市場概要
- 市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
主な市場の考察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- IP分析
- 貿易分析
- スタートアップ分析
- 原材料の分析
- イノベーションマトリクス
- パイプライン製品の分析
- マクロ経済指標
- 主な投資の分析
- 主な成功要因
- 競合の程度
市場力学と見通し
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 規制情勢
- ポーターの分析
- 将来の混乱についての特別な考察
経動脈的化学塞栓療法の世界市場：製品別
- 市場概要
- 病院
- 外来手術センター
- 専門クリニック
経動脈的化学塞栓療法の世界市場：エンドユーザー別
- 市場概要
- いちご
- りんご
- マンゴー
- ミックスフルーツブレンド
- 柑橘類
- エキゾチックフルーツ
経動脈的化学塞栓療法の世界市場：技術別
- 市場概要
- リピオドールベースのTACE
- 薬剤溶出ビーズTACE技術
経動脈的化学塞栓療法の世界市場規模：地域別
- 市場概要
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他の欧州
- アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他のアジア太平洋
- ラテンアメリカ
- ブラジル
- その他のラテンアメリカ
- 中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域
競合情勢
- 上位5社の比較
- 主要企業の市場ポジショニング（2023年）
- 主な市場企業が採用した戦略
- 主要成功戦略
- 市場における最近の活動
- 主要企業の市場シェア（2023年）
主要企業プロファイル
- Boston Scientific Corporation（US）
- Terumo Corporation（Japan）
- Cook Medical（US）
- Cardinal Health（US）
- Becton, Dickinson and Company（US）
- Guerbet（France）
- AngioDynamics, Inc.（US）
- SIRtex Medical Inc.（Australia）
- Merit Medical Systems Inc.（US）
- Varian Medical Systems, Inc.（US）
- Microvena Therapeutics, Inc.（US）
- RadioMed LLC（US）
- IGT Laboratories（US）
- MicroCath, Inc.（US）
- Spectranetics, Inc.（US）
- Penumbra, Inc.（US）
- Oncotreat SA（Switzerland）
- Vascular Dynamics, Inc.（US）
- Shanghai Jahva Medical Co., Ltd.（China）
- Hangzhou Micro-Tech Co., Ltd.（China）
Global Transarterial Chemoembolization Market size was valued at USD 16.88 billion in 2022 and is poised to grow from USD 17.81 billion in 2023 to USD 27.33 billion by 2031, growing at a CAGR of 5.5% in the forecast period (2024-2031).
The global transarterial chemoembolization (TACE) market is experiencing significant growth and evolution driven by a multitude of factors. TACE, a minimally invasive procedure used primarily in the treatment of liver cancer, has witnessed a surge in demand due to the rising incidence of liver cancer worldwide. Factors such as increasing alcohol consumption, prevalence of hepatitis B and C infections, and changing lifestyles contribute to the growing burden of liver cancer. Additionally, advancements in medical technology and techniques have enhanced the efficacy and safety of TACE procedures, further fueling market expansion. Moreover, the rising adoption of combination therapies, including TACE in conjunction with other treatments such as radiofrequency ablation or immunotherapy, is broadening the scope of its application and driving market growth. Furthermore, favorable reimbursement policies for TACE procedures in several countries, coupled with ongoing research and development initiatives to improve treatment outcomes, are expected to sustain market momentum. However, challenges such as limited accessibility to advanced healthcare facilities in certain regions and the high cost associated with TACE procedures may hinder market growth to some extent. Overall, with continuous innovations and a growing focus on personalized medicine, the global TACE market is poised for further advancement in the foreseeable future.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Transarterial Chemoembolization Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Transarterial Chemoembolization Market Segmental Analysis
The global transarterial chemoembolization market is segmented into four major segments i.e. by end-user, product type, technology, and region. Based on end-user, it is divided into hospitals, ambulatory surgical centers, specialty clinics. Based on product type, it is bifurcated as catheters, guidewires, microcatheters, embolic agents, chemotherapeutic agents. Based on technology it is segregated into, lipiodol-based TACE, drug-eluting bead TACE technology. Based on region, the market is segmented into North America, Europe, Asia-Pacific, Latin America, Middle East & Africa.
Drivers of the Global Transarterial Chemoembolization Market
The global rise in liver cancer cases and the need for treatments like TACE. Furthermore, as medical procedures continue to advance, the precision and effectiveness of these treatment methods are enhanced, making them more appealing to both patients and doctors. Because minimally invasive techniques assist patients avoid the discomfort associated with traditional treatment approaches, they have also emerged as important drivers of TACE.
Restraints in the Global Transarterial Chemoembolization Market
One of the main market barriers in this instance is the variety of individuals with liver cancer cases and their complexity as a result of differing treatment responses. The degree of intricacy linked with TACE has the potential to limit its applicability and need a customized approach, which might eventually impede its widespread adoption. Strict national restrictions regarding the authorization and payment of medical operations present additional difficulty and limitation. Prolonged regulatory procedures and disparities in reimbursement techniques might make it difficult to integrate TACE into ordinary health care delivery.
Market Trends of the Global Transarterial Chemoembolization Market
The movement in liver cancer treatment toward customized care. Healthcare professionals are investigating tailored TACE depending on patient characteristics and overall health state, including tumor kinds. The general move toward precision medicine to optimize patient outcomes is supported by this trend. The TACE market is also seeing a significant trend in technical improvements. This enhances TACE's performance, which is a continuous research project to increase its accuracy and potency. The most recent advancements in drug-eluting bead and imaging technologies, together with embolic agents, enable to target malignant spots so that therapy can be successful with the least amount of harm to surrounding tissues and organs.
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Global Transarterial Chemoembolization Market by Product
- Market Overview
- Hospitals
- Ambulatory Surgical Centers
- Specialty Clinics
Global Transarterial Chemoembolization Market by End-User
- Market Overview
- Strawberry
- apple
- mango
- mixed fruit blends
- citrus
- and exotic fruits
Global Transarterial Chemoembolization Market by Technology
- Market Overview
- Lipiodol-based TACE
- Drug-Eluting Bead TACE Technology
Global Transarterial Chemoembolization Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2023
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2023
Key Company Profiles
- Boston Scientific Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Terumo Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cook Medical (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cardinal Health (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Becton, Dickinson and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Guerbet (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AngioDynamics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- SIRtex Medical Inc. (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merit Medical Systems Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Varian Medical Systems, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Microvena Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- RadioMed LLC (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- IGT Laboratories (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- MicroCath, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Spectranetics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Penumbra, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Oncotreat SA (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Vascular Dynamics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Shanghai Jahva Medical Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Hangzhou Micro-Tech Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
